Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 crossover trial of recombinant human C1 inhibitor (Ruconest) for prophylaxis of hereditary angioedema attacks
2014-002839-33Phase 2Completed
- Sponsor
- Pharming Group
- Start
- Mar 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hereditary angioedema (HAE) comparing Ruconest with Saline placebo (2 arms). Primary endpoint: Number of HAE attacks per 28-day period. Started Mar 2015; status: completed.
02
Drugs
c1-esterase inhibitor
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on 2014-002839-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002839-33.